Alzheimer's Disease Diagnostic Reagents

About Aptamer Group

Aptamer Group's mission is to overcome targeting challenges in life sciences by providing next-generation aptamer reagents and solutions. The company has achieved significant validation, claiming to work with 100% of the top 10 global pharmaceutical companies, and has demonstrated its technology in areas from Alzheimer's diagnostics to targeted siRNA delivery with AstraZeneca. Its strategy is to capture value in the $210 billion affinity ligand market through a fee-for-service and licensing model, progressing select programs into therapeutic development.

Therapeutic Areas